Tesamorelin vs Somatropin
Tesamorelin is a synthetic analogue of human growth hormone-releasing factor that acts on the pituitary to stimulate endogenous, pulsatile growth hormone secretion, and it is approved for a single indication: excess abdominal fat in people with HIV-associated lipodystrophy. Somatropin is recombinant human growth hormone itself, the 191-amino-acid protein that has been an approved therapeutic since the mid-1980s across childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and other short-stature indications. The two are placed side by side because they engage the same endocrine axis from opposite ends, and because both were tested for visceral fat accumulation in HIV during the same period. No randomised trial has given both to the same participants or randomised participants between them. What exists instead is one systematic review that pooled placebo-controlled trials across the whole growth hormone axis, and a series of narrative reviews that describe the two treatments in parallel and comment on how their risk profiles differ.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published trial has administered tesamorelin and recombinant human growth hormone to the same participants, and none has randomised participants between the two agents. The closest published comparison is indirect. Sivakumar and colleagues pooled ten randomised placebo-controlled trials including 1,511 patients with HIV-associated lipodystrophy in which the intervention was growth hormone, growth hormone-releasing hormone, tesamorelin or IGF-1, and reported that growth hormone axis treatment as a class reduced visceral adipose tissue and increased lean body mass relative to placebo while leaving subcutaneous adipose tissue unchanged. Subgroup analysis by drug class reported that growth hormone itself had the most pronounced effects on visceral and subcutaneous fat but no effect on lean body mass, and the authors identified the small number of trials available for each class as a limitation. Because every included trial compared its own drug against placebo rather than against the other drug, that subgroup contrast is a comparison across separate studies rather than a randomised head-to-head result. The remaining publications that engage both compounds are narrative reviews of HIV-associated fat accumulation and of the ageing growth hormone axis. Several of them describe the growth hormone-releasing factor analogue as better tolerated than supraphysiological recombinant growth hormone, but none reports a controlled comparison of the two.
The 9 publications that cover both
- 01Systematic review2011
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials
Sivakumar T, et al. · HIV Medicine · systematic review and meta-analysis of 10 randomised placebo-controlled trials, 1,511 patients with HIV-associated lipodystrophy, covering growth hormone, growth hormone-releasing hormone, tesamorelin and IGF-1
Growth hormone axis treatments reduced visceral adipose tissue relative to placebo (weighted mean difference -25.20 cm2, 95% CI -32.18 to -18.22) and increased lean body mass (1.31 kg, 95% CI 1.00 to 1.61), with no significant effect on subcutaneous adipose tissue. Subgroup analysis by drug class reported that growth hormone had the most significant effects on visceral and subcutaneous fat but none on lean body mass. Arthralgia and oedema were the statistically significant adverse effects, and the authors listed the small number of studies available for each drug class as a limitation.
- 02Review2017
Growth hormone deficiency and human immunodeficiency virus
Rochira V, et al. · Best Practice & Research. Clinical Endocrinology & Metabolism · historical and narrative review of growth hormone and IGF-1 axis function in HIV infection
The review reported that both spontaneous growth hormone secretion and the response to provocative stimuli were reduced in people with HIV, particularly those with lipodystrophy. It described tesamorelin as effective in reducing visceral fat in that population and characterised the approach as promising and safer than treatment with high doses of recombinant human growth hormone, which the authors said carried several side effects.
- 03Review2010
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection
Moyle G, et al. · AIDS Reviews · review of Medline and conference-abstract literature on factors associated with visceral adiposity in HIV and on randomised management studies
The review reported that supraphysiological recombinant human growth hormone and the growth hormone-releasing hormone analogue tesamorelin both significantly and selectively reduced visceral fat in randomised studies lasting up to 24 weeks, and that the benefit was maintained only while treatment continued. The authors concluded that prevention and management of visceral adiposity remained a substantial challenge in clinical practice.
- 04Review2012
Pathogenesis and treatment of human immunodeficiency virus lipodystrophy
Jain SS, et al. · Indian Journal of Endocrinology and Metabolism · narrative review of HIV lipodystrophy syndrome and the hormone-related drugs used to treat it
The review described a study in which 325 patients with HIV and increased visceral adipose tissue received supraphysiological recombinant human growth hormone, and a second study of physiological dosing in patients with low growth hormone levels, reporting significant reductions in visceral fat alongside evidence of insulin resistance. It then set out tesamorelin as a more promising approach to growth hormone modulation, binding growth hormone-releasing factor receptors with potency similar to the endogenous peptide and stimulating pulsatile release of endogenous growth hormone.
- 05Review2009
Tesamorelin, a human growth hormone releasing factor analogue
Wang Y, et al. · Expert Opinion on Investigational Drugs · drug-development review drawing on medical and chemical literature databases and on references from published articles
The authors stated that growth hormone-releasing factor analogues were developed because recombinant human growth hormone combined clinical effectiveness with a variety of adverse effects, and that such analogues might be better tolerated. They reported that a multicentre randomised placebo-controlled phase 3 trial supported tesamorelin for HIV-related lipodystrophy, and that other potential indications appeared less promising on the data then available.
- 06Review2013
Growth hormone in the aging male
Sattler FR · Best Practice & Research. Clinical Endocrinology & Metabolism · critical review of growth hormone augmentation during ageing, with emphasis on men
The review reported that a limited number of controlled studies of growth hormone supplementation in older men showed increases in lean mass of approximately two kilograms with similar reductions in fat mass, and little evidence of improved muscle strength, walking speed, stair-climbing ability or quality of life. It described tesamorelin separately as restoring normal growth hormone pulsatility and amplitude, selectively reducing visceral fat, intima media thickness and triglycerides, and improving cognitive function in older persons.
- 07Review2009
Treatment options for HIV-associated central fat accumulation
Cofrancesco J Jr, et al. · AIDS Patient Care and STDs · narrative review of interventions evaluated for HIV-associated central fat accumulation
The review reported that two large randomised controlled trials had demonstrated the efficacy of recombinant human growth hormone in reducing visceral adipose tissue, and described the data then available for growth hormone-releasing hormone as promising. It also recorded that no drug had been approved for the treatment of HIV-associated central fat accumulation at the time of writing, and that lifestyle modification and antiretroviral switching appeared to be of limited value.
- 08Review2011
Growth hormone and HIV infection: contribution to disease manifestations and clinical implications
Falutz J · Best Practice & Research. Clinical Endocrinology & Metabolism · review of growth hormone biology in HIV and of growth hormone and growth hormone-releasing factor as therapeutic agents
The review reported that growth hormone deficiency contributed to loss of lean and fat mass in untreated HIV infection and that pharmacologic doses of growth hormone reversed that wasting process. It described treatment with growth hormone and with growth hormone-releasing factor as producing short-term improvement in truncal obesity, dyslipidaemia and glucose homeostasis changes in treated patients, while noting the multifactorial aetiology of those abnormalities.
- 09Review2008
The next generation of human growth hormone. How Serostim and tesamorelin measure up
Grodeck B · Positively Aware · patient-facing article in an HIV community journal setting a marketed recombinant growth hormone product against tesamorelin, which was still investigational at the time of publication
The article was written as a direct comparison of the marketed recombinant human growth hormone product and tesamorelin for HIV-associated body composition change. No abstract is indexed for the record, so the published title is the only part of its content that can be verified against PubMed.
Side by side.
| Tesamorelin | Somatropin | |
|---|---|---|
| Evidence maturity | Approved drug | Approved drug |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 11 | 13 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 44-amino-acid synthetic analogue of human growth hormone-releasing factor, modified by addition of a trans-3-hexenoyl group to the N-terminal tyrosine, which non-clinical work reported made the peptide resistant to dipeptidyl aminopeptidase-IV degradation and prolonged its plasma kinetics. | The 191-amino-acid recombinant form of human growth hormone itself, produced to match the sequence of the pituitary hormone and replacing the cadaveric pituitary extracts used before the recombinant era. |
| Mechanism as described in the literature | Acts upstream, at the growth hormone-releasing hormone receptor on pituitary somatotrophs, so growth hormone release remains pulsatile and subject to feedback and somatostatin regulation. | Acts downstream, at the growth hormone receptor and the JAK/STAT pathway, largely through hepatic and local induction of IGF-1, bypassing pituitary control entirely. |
| Size of the evidence base | Concentrated on one indication. Two multicentre phase 3 trials with extension phases anchor the literature, followed by investigator-initiated trials in hepatic fat and cognition; the two 2026 meta-analyses pooled four and five randomised controlled trials respectively. | One of the larger clinical evidence bases in endocrinology, spanning several approved indications since the mid-1980s and dominated by systematic reviews, network meta-analyses and consensus statements, with registry surveillance running to tens of thousands of patient-years. |
| Best-characterised finding | Reduction in visceral adipose tissue in people with HIV and abdominal fat accumulation, with the pivotal trial reporting a 15.2% decrease against a 5.0% increase on placebo, and hepatic fat reduction in later randomised trials. | Linear growth response in growth hormone deficiency, and in adults a body composition shift, with the 1989 controlled trial reporting an increase in lean body mass of roughly 5.5 kg and a fall in fat mass of roughly 5.7 kg over six months. |
| Human data | Randomised placebo-controlled trials exist for visceral and hepatic fat in HIV. Cognitive trials have been small and inconsistent, and the largest HIV neurocognitive trial found no significant between-group difference. | Randomised trials and long-term registries across childhood and adult deficiency, Turner syndrome, Prader-Willi syndrome and small-for-gestational-age short stature, plus consensus statements adjudicating that evidence. |
| Safety signals reported | Arthralgia, myalgia, paraesthesia, injection-site reactions and IGF-1 elevation were recorded in the pooled trial analyses, and glucose homeostasis remains a monitored concern. | Registry surveillance reported adverse drug reactions in 7.0% of participants and serious reactions in 0.3%, with a malignancy standardised incidence ratio of 1.1; a consensus statement found the reviewed evidence did not support an association with tumour recurrence in cancer survivors while recommending continued surveillance. |
| Regulatory status | Approved for one indication, the reduction of excess abdominal fat in HIV-associated lipodystrophy. No approval exists for ageing, body composition or performance use, and growth hormone-releasing factor analogues are prohibited in sport. | Approved since the mid-1980s across several deficiency and short-stature indications, with an active regulatory literature comparing daily dosing against once-weekly long-acting analogues. Growth hormone is likewise prohibited in sport. |
| Basis of most marketing claims | Extension of a visceral-fat result obtained in HIV-associated lipodystrophy to general body composition, ageing and cognition, where the controlled evidence is small, mixed or absent. | Extension of deficiency-replacement data to people with normal growth hormone secretion, a population in which the reviewed controlled studies reported modest body composition change without demonstrable gains in strength, function or quality of life. |
And what it does not.
Nothing in the published record ranks these two against each other, because no trial has run them side by side. What the separate literatures support is asymmetric. Somatropin has the older, larger and more heavily adjudicated evidence base, built on deficiency states in which replacement corrects a measurable shortfall, and its risks have been tracked in registries covering tens of thousands of patient-years. Tesamorelin has a narrower but genuinely randomised evidence base confined largely to visceral and hepatic fat in HIV, and the reviews that discuss both describe it as the better tolerated of the two, since it leaves pituitary feedback intact. The one pooled analysis to include both classes found growth hormone axis treatment reduced visceral fat and increased lean mass relative to placebo, with growth hormone driving the fat effect, but its subgroups were small and assembled from separate placebo-controlled studies rather than from a comparison. Neither compound has controlled evidence for the ageing, physique or performance uses that prompt the comparison in the first place.
Common questions.
- Has any trial randomised participants between tesamorelin and recombinant growth hormone?
No. Searches of PubMed and Europe PMC returned no trial that administered both agents to the same participants and none that randomised participants between them. The published trials of each drug used a placebo comparator. The only pooled analysis to include both, a 2011 systematic review of ten placebo-controlled trials in HIV-associated lipodystrophy, compared each class against placebo and then contrasted the classes in a subgroup analysis, which is a comparison across separate studies rather than a randomised head-to-head result.
- Why do reviews describe the releasing-factor approach as better tolerated?
Because it acts one step earlier in the axis. Tesamorelin stimulates the pituitary to release its own growth hormone, so secretion stays pulsatile and remains subject to feedback and somatostatin regulation, whereas recombinant growth hormone is delivered directly and bypasses that control. Reviews of HIV-associated fat accumulation reported that supraphysiological recombinant growth hormone reduced visceral fat but was accompanied by evidence of insulin resistance, and described the analogue as the safer of the two. That comparison is drawn across studies rather than from a trial.
- Do the two drugs have the same approved indications?
They do not overlap at all. Tesamorelin is approved for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy and for nothing else. Somatropin is approved across childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature, depending on jurisdiction. No regulator has approved either compound for ageing, athletic performance or body recomposition in people with normal growth hormone secretion.
- What happened when tesamorelin was tested outside HIV-associated fat accumulation?
The results have been mixed. Randomised work extended the compound to hepatic fat in fatty liver disease in people with HIV, where hepatic fat fraction fell relative to placebo. Cognitive trials have been small: an earlier controlled trial reported a favourable effect on a composite cognitive measure, a 2026 randomised study in 22 adults found no significant change over ten weeks, and a phase 2 trial in people with HIV and abdominal obesity found no significant between-group difference. A trial combining the compound with exercise has published its protocol but no results.
- Does the growth hormone literature support use in people who are not deficient?
The reviewed controlled studies do not support it strongly. A review of growth hormone in ageing men reported that supplementation increased lean mass by roughly two kilograms with a similar reduction in fat mass, but found little evidence of improved muscle strength, walking speed, stair-climbing ability or quality of life. Long-term outcome data in that group are absent, and the consensus and registry literature for somatropin concerns approved deficiency indications rather than augmentation in people with normal secretion.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.